Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals Inc. is a Canadian-founded biopharmaceutical company that was acquired by AstraZeneca in June 2024, becoming a wholly-owned subsidiary. Headquartered in Hamilton, Ontario, Canada, with additional operations in the US, the company was founded in 2014. Prior to its acquisition, Fusion Pharmaceuticals was publicly traded on Nasdaq (FUSN) and had approximately 106 employees with annual revenue around $2.07 million as of December 31, 2023. The acquisition by AstraZeneca was valued at approximately $2.4 billion.

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation targeted radioconjugates (RCs) as precision medicines for cancer. Their proprietary Fast-Clear™ linker technology connects alpha-particle-emitting medical isotopes to targeting molecules, designed to deliver radiation directly and precisely to cancer cells while minimizing toxicity to healthy tissues. Key product candidates in their pipeline include FPI-2265, an actinium-225 based PSMA-targeting radioconjugate in Phase 2/3 trials for metastatic castration-resistant prostate cancer, and FPI-1434 and FPI-2059, which are in earlier clinical stages for various solid tumors.

The company's patent litigation posture, based on tracked cases, indicates an active role as a plaintiff. Fusion Pharmaceuticals, Inc. has appeared in one tracked case as a plaintiff and zero as a defendant. This single plaintiff case, Fusion Pharmaceuticals, Inc. v. European Atomic Energy Community Euratom et al., was filed in February 2023 at the Patent Trial and Appeal Board (PTAB). This suggests the company actively engages in challenging patents through administrative proceedings, likely to support its therapeutic development or address intellectual property relevant to its field.

A significant contextual event is the recent acquisition by AstraZeneca, announced in March 2024 and completed in June 2024, which aims to accelerate AstraZeneca's radiopharmaceutical pipeline and strengthen its presence in the oncology space. The PTAB case against European Atomic Energy Community Euratom et al. aligns with an operating company's strategic use of patent challenges.